Jeffrey Foy

Corporate Officer/Principal at PEPGEN INC.

Health Technology

Consumer Services

Commercial Services

Profile

Jeffrey Foy is a member of the Oligonucleotide Therapeutics Society, Inc. and the Vice President-Toxicology at PepGen Inc. He was previously an Executive Director-Toxicology at Dicerna Pharmaceuticals, Inc. He has a graduate degree from Northeastern University and an undergraduate degree from the University of Vermont.

Jeffrey Foy active positions

Companies	Position	Start
PEPGEN INC.	Corporate Officer/Principal	-
Oligonucleotide Therapeutics Society, Inc. Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators.	Corporate Officer/Principal	-

All active positions of Jeffrey Foy

Former positions of Jeffrey Foy

Companies	Position	End
DICERNA PHARMACEUTICALS, INC.	Corporate Officer/Principal	-

See the detail of Jeffrey Foy's experience

Training of Jeffrey Foy

Northeastern University	Graduate Degree
University of Vermont	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jeffrey Foy's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
PEPGEN INC.	Health Technology

Private companies	2
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.	Health Technology
Oligonucleotide Therapeutics Society, Inc. Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators.	Commercial Services